Navigation Links
Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
Date:5/11/2009

ould affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  David Knutson
              651-582-6572 (office)
              651-260-8288 (mobile)
              Media Relations
              Boston Scientific Corporation

              Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

              Larry Neumann

'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Xconomy Launches XSITE 2009; First Annual Xconomy Summit on Innovation, Technology, and Entrepreneurship at Boston University
2. UMass Boston Opens Venture Development Center to Expand R&D Activity
3. Boston Scientific Announces First Quarter Special Items
4. Boston Scientific Launches New Coronary Imaging Catheter
5. Moodys Raises Boston Scientifics Rating Outlook to Stable
6. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University
7. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
8. Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory
9. Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge
10. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
11. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)...  Champions Oncology (OTC-BB: CSBR), a company engaged in ... personalize the development and use of oncology drugs, today ... for the fourth quarter and fiscal year quarter ended ... market open. The company will host a ... 9:00 a.m. EDT (6:00 a.m. PDT). To participate in ...
(Date:7/24/2015)... China , July 24, 2015 ... manufacturing platform , Expands product offering for chronic ... unmet medical needs in diabetes-related complications and dermatology ... 3SBio Inc., (HKEX:1530) ("3SBio" or ,the Company"), a leading ... researching, developing, manufacturing and marketing biopharmaceutical products, today announced ...
(Date:7/23/2015)... ... July 23, 2015 , ... Science and technology continue to improve all aspects ... devices – according to Susan Chang, MD, director of the Division of Neuro-oncology at ... new technology are impacting the development of new treatments and advancing strategies to minimize ...
(Date:7/23/2015)... (PRWEB) , ... July 23, 2015 , ... The Pittcon ... the Harry S. Mosher Professor of Chemistry and Professor, by courtesy, of Applied Physics ... Optical Single-Molecule Detection in Solids Led to Super-Resolution Nanoscopy in Cells and Beyond” , ...
Breaking Biology Technology:Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 23SBio Acquires Zhejiang Wansheng Pharmaceutical 23SBio Acquires Zhejiang Wansheng Pharmaceutical 33SBio Acquires Zhejiang Wansheng Pharmaceutical 4Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 2The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 3
... , KNOXVILLE, Tenn., Sept. 16 Marking ... colon cancer, EDP Biotech Corporation (EDP), ... today that its ColoMarker(TM) assay achieved 100 percent detection rate ... pre-clinical trials. ColoMarker is the first assay of its kind ...
... SAN DIEGO, Sept. 16 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: ... new class of small molecule compounds based on endogenous adrenal steroid ... Stock Market on September 15, 2009. , , ... Marketplace Rule 4450(a)(5) (the "Minimum Bid Price Rule") because its common ...
... Collaboration with Biomodels facilitates development of novel drug product , ... Inc., a biotechnology company developing oral antibodies for disease targets accessible ... a Phase I SBIR grant from the National Institute of Dental ... therapeutic for oral mucositis. , , Avaxia is ...
Cached Biology Technology:New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials 2New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials 3Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 2Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 3Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 2Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 3
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... personalized medicine for Parkinson,s disease, by investigating signs of ... cells respond to drug treatments. The study was funded ... collected skin cells from patients with genetically inherited forms ... They found that neurons derived from individuals with distinct ...
... is the way to go, if you are a primate ... orangutans, researchers have measured the energy required to navigate a ... up in the trees. Their work was presented at the ... July 2012. The findings help us to understand ...
... Laboratory of Neuro Imaging (LONI) has been responsible for ... generated by the Alzheimer,s Disease Neuroimaging Initiative (ADNI), an ... of Alzheimer,s disease. That stream of ... partners with an ambitious publicprivate effort to dig deeper ...
Cached Biology News:Patient-derived stem cells could improve drug research for Parkinson's 2Patient-derived stem cells could improve drug research for Parkinson's 3Patient-derived stem cells could improve drug research for Parkinson's 4Revolutionary project will obtain entire genome sequences in fight against Alzheimer's 2Revolutionary project will obtain entire genome sequences in fight against Alzheimer's 3
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
Request Info...
...
Biology Products: